Athira Pharma(ATHA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mildto-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., August 1, 2024 – Athi ...